{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:38:21Z","timestamp":1767141501451,"version":"build-2238731810"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s11239-017-1582-1","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T10:28:53Z","timestamp":1511346533000},"page":"77-87","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Generation and characterization of tissue-type plasminogen activator transgenic rats"],"prefix":"10.1007","volume":"45","author":[{"given":"Yusuke","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoji","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"key":"1582_CR1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.2005.05444.x","volume":"129","author":"G Cesarman-Maus","year":"2005","unstructured":"Cesarman-Maus G, Hajjar KA (2005) Molecular mechanisms of fibrinolysis. Br J Haematol 129:307\u2013321","journal-title":"Br J Haematol"},{"key":"1582_CR2","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/STR.0b013e318284056a","volume":"44","author":"EC Jauch","year":"2013","unstructured":"Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM et al (2013) Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 44:870\u2013947","journal-title":"Stroke"},{"key":"1582_CR3","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.drudis.2014.05.025","volume":"19","author":"T Wyseure","year":"2014","unstructured":"Wyseure T, Declerck PJ (2014) Novel or expanding current targets in fibrinolysis. Drug Discov Today 19:1476\u20131482","journal-title":"Drug Discov Today"},{"key":"1582_CR4","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1055\/s-0038-1649973","volume":"74","author":"J Kuiper","year":"1995","unstructured":"Kuiper J, van de Bilt H, Martin U, van Berkel TJ (1995) Uptake, internalization and degradation of the novel plasminogen activator reteplase (BM 06.022) in the rat. Thromb Haemost 74:1501\u20131510","journal-title":"Thromb Haemost"},{"key":"1582_CR5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/01.CIR.84.1.244","volume":"84","author":"SJ Gardell","year":"1991","unstructured":"Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC et al (1991) Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 84:244\u2013253","journal-title":"Circulation"},{"key":"1582_CR6","doi-asserted-by":"crossref","first-page":"8292","DOI":"10.1073\/pnas.84.23.8292","volume":"84","author":"HL Wu","year":"1987","unstructured":"Wu HL, Shi GY, Bender ML (1987) Preparation and purification of microplasmin. Proc Natl Acad Sci USA 84:8292\u20138295","journal-title":"Proc Natl Acad Sci USA"},{"key":"1582_CR7","doi-asserted-by":"crossref","first-page":"832","DOI":"10.7164\/antibiotics.56.832","volume":"56","author":"W Hu","year":"2003","unstructured":"Hu W, Kitano Y, Hasumi K (2003) SMTP-4D, -5D, -6D, -7D and -8D, a new series of the non-lysine-analog plasminogen modulators with a D-amino acid moiety. J Antibiot (Tokyo) 56:832\u2013837","journal-title":"J Antibiot (Tokyo)"},{"key":"1582_CR8","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1124\/jpet.103.062729","volume":"309","author":"K Suzuki","year":"2004","unstructured":"Suzuki K, Muto Y, Fushihara K, Kanemoto K, Iida H, Sato E et al (2004) Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B. J Pharmacol Exp Ther 309:607\u2013615","journal-title":"J Pharmacol Exp Ther"},{"key":"1582_CR9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1160\/TH06-09-0551","volume":"97","author":"YX Wang","year":"2007","unstructured":"Wang YX, Zhao L, Nagashima M, Vincelette J, Sukovich D, Li W et al (2007) A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)\u2014part I: pharmacological characterization. Thromb Haemost 97:45\u201353","journal-title":"Thromb Haemost"},{"key":"1582_CR10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1160\/TH06-09-0552","volume":"97","author":"YX Wang","year":"2007","unstructured":"Wang YX, da Cunha V, Vincelette J, Zhao L, Nagashima M, Kawai K et al (2007) A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa)\u2014part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost 97:54\u201361","journal-title":"Thromb Haemost"},{"key":"1582_CR11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.thromres.2006.11.010","volume":"120","author":"E Bird","year":"2007","unstructured":"Bird E, Tamura J, Bostwick JS, Steinbacher TE, Stewart A, Liu Y et al (2007) Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats? Thromb Res 120:549\u2013558","journal-title":"Thromb Res"},{"key":"1582_CR12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1474-4422(15)00047-2","volume":"14","author":"GW Albers","year":"2015","unstructured":"Albers GW, von Kummer R, Truelsen T, Jensen JK, Ravn GM, Gr\u00f8nning BA et al (2015) Safety and efficacy of desmoteplase given 3\u20139 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol 14:575\u2013584","journal-title":"Lancet Neurol"},{"key":"1582_CR13","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1161\/STROKEAHA.109.560201","volume":"40","author":"VN Thijs","year":"2009","unstructured":"Thijs VN, Peeters A, Vosko M, Aichner F, Schellinger PD, Schneider D et al (2009) Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke. Stroke 40:3789\u20133795","journal-title":"Stroke"},{"key":"1582_CR14","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/00001756-199210000-00027","volume":"3","author":"K Overgaard","year":"1992","unstructured":"Overgaard K, Sereghy T, Pedersen H, Boysen G (1992) Dose-response of rt-PA and its combination with aspirin in a rat embolic stroke model. Neuroreport 3:925\u2013928","journal-title":"Neuroreport"},{"key":"1582_CR15","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/jcbfm.2010.33","volume":"30","author":"B Haelewyn","year":"2010","unstructured":"Haelewyn B, Risso JJ, Abraini JH (2010) Human recombinant tissue-plasminogen activator (alteplase): why not use the \u2018human\u2019 dose for stroke studies in rats? J Cereb Blood Flow Metab 30:900\u2013903","journal-title":"J Cereb Blood Flow Metab"},{"key":"1582_CR16","doi-asserted-by":"crossref","first-page":"16026","DOI":"10.1038\/srep16026","volume":"5","author":"AJ Tomkins","year":"2015","unstructured":"Tomkins AJ, Hood RJ, Levi CR, Spratt NJ (2015) Tissue Plasminogen Activator for preclinical stroke research: neither \u201crat\u201d nor \u201chuman\u201d dose mimics clinical recanalization in a carotid occlusion model. Sci Rep 5:16026","journal-title":"Sci Rep"},{"key":"1582_CR17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1055\/s-0038-1653411","volume":"46","author":"C Korninger","year":"1981","unstructured":"Korninger C, Collen D (1981) Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 46:561\u2013565","journal-title":"Thromb Haemost"},{"key":"1582_CR18","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood-2008-02-141630","volume":"112","author":"J An","year":"2008","unstructured":"An J, Zhang C, Polavarapu R, Zhang X, Zhang X, Yepes M (2008) Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain. Blood 112:2787\u20132794","journal-title":"Blood"},{"key":"1582_CR19","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm926","volume":"9","author":"X Wang","year":"2003","unstructured":"Wang X, Lee SR, Arai K, Lee SR, Tsuji K, Rebeck GW et al (2003) Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9:1313\u20131317","journal-title":"Nat Med"},{"key":"1582_CR20","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1074\/jbc.M504988200","volume":"281","author":"K Hu","year":"2006","unstructured":"Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y (2006) Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 281:2120\u20132127","journal-title":"J Biol Chem"},{"key":"1582_CR21","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1172\/JCI116893","volume":"92","author":"P Carmeliet","year":"1993","unstructured":"Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M et al (1993) Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92:2756\u20132760","journal-title":"J Clin Invest"},{"key":"1582_CR22","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood.V93.7.2274","volume":"93","author":"HR Lijnen","year":"1999","unstructured":"Lijnen HR, Okada K, Matsuo O, Collen D, Dewerchin M (1999) Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 93:2274\u20132281","journal-title":"Blood"},{"key":"1582_CR23","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1093\/emboj\/18.11.3007","volume":"18","author":"R Madani","year":"1999","unstructured":"Madani R, Hulo S, Toni N, Madani H, Steimer T, Muller D et al (1999) Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J 18:3007\u20133012","journal-title":"EMBO J"},{"issue":"4","key":"1582_CR24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nbt804","volume":"21","author":"G Testa","year":"2003","unstructured":"Testa G, Zhang Y, Vintersten K, Benes V, Pijnappel WW, Chambers I et al (2003) Engineering the mouse genome with bacterial artificial chromosomes to create multipurpose alleles. Nat Biotechnol 21(4):443\u2013447","journal-title":"Nat Biotechnol"},{"key":"1582_CR25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/01.STR.20.1.84","volume":"20","author":"EZ Longa","year":"1989","unstructured":"Longa EZ, Weinstein PR, Carlson S, Cummins R (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:84\u201391","journal-title":"Stroke"},{"key":"1582_CR26","doi-asserted-by":"publisher","unstructured":"Yang XW, Gong S (2005) An overview on the generation of BAC transgenic mice for neuroscience research. Curr Protoc Neurosci. https:\/\/doi.org\/10.1002\/0471142301.ns0520s31","DOI":"10.1002\/0471142301.ns0520s31"},{"key":"1582_CR27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature02033","volume":"425","author":"S Gong","year":"2003","unstructured":"Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB et al (2003) A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425:917\u2013925","journal-title":"Nature"},{"key":"1582_CR28","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0090-9556(24)15191-4","volume":"28","author":"K Oikawa","year":"2000","unstructured":"Oikawa K, Watanabe T, Higuchi S (2000) Comparison of drug disposition between wild-type and novel tissue-type plasminogen activator pamiteplase in rats. Drug Metab Dispos 28:1087\u20131093","journal-title":"Drug Metab Dispos"},{"key":"1582_CR29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.vascn.2005.06.006","volume":"53","author":"SA Sturgeon","year":"2006","unstructured":"Sturgeon SA, Jones C, Angus JA, Wright CE (2006) Adaptation of the Folts and electrolytic methods of arterial thrombosis for the study of anti-thrombotic molecules in small animals. J Pharmacol Toxicol Methods 53:20\u201329","journal-title":"J Pharmacol Toxicol Methods"},{"key":"1582_CR30","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/01.STR.0000258112.14918.24","volume":"38","author":"JH Rha","year":"2007","unstructured":"Rha JH, Saver JL (2007) The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 38:967\u2013973","journal-title":"Stroke"},{"key":"1582_CR31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1055\/s-0038-1648820","volume":"72","author":"JH Wu","year":"1994","unstructured":"Wu JH, Siddiqui K, Diamond SL (1994) Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis. Thromb Haemost 72:105\u2013112","journal-title":"Thromb Haemost"},{"key":"1582_CR32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/157340310791658730","volume":"6","author":"A Arboix","year":"2010","unstructured":"Arboix A, Ali\u00f3 J (2010) Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. Curr Cardiol Rev 6:150\u2013161","journal-title":"Curr Cardiol Rev"},{"key":"1582_CR33","doi-asserted-by":"crossref","first-page":"494","DOI":"10.4103\/0972-2327.120433","volume":"16","author":"P Singh","year":"2013","unstructured":"Singh P, Kaur R, Kaur A (2013) Clot composition and treatment approach to acute ischemic stroke: the road so far. Ann Indian Acad Neurol 16:494\u2013497","journal-title":"Ann Indian Acad Neurol"},{"key":"1582_CR34","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/jcbfm.2010.116","volume":"30","author":"ES Sena","year":"2010","unstructured":"Sena ES, Briscoe CL, Howells DW, Donnan GA, Sandercock PA, Macleod MR (2010) Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. J Cereb Blood Flow Metab 30:1905\u20131913","journal-title":"J Cereb Blood Flow Metab"},{"key":"1582_CR35","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1016\/j.jacc.2015.12.077","volume":"67","author":"M Mokin","year":"2016","unstructured":"Mokin M, Snyder KV, Siddiqui AH, Levy EI, Hopkins LN (2016) Recent endovascular stroke trials and their impact on stroke systems of care. J Am Coll Cardiol 67:2645\u20132655","journal-title":"J Am Coll Cardiol"}],"updated-by":[{"DOI":"10.1007\/s11239-017-1598-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T00:00:00Z","timestamp":1513382400000}}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-017-1582-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-017-1582-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-017-1582-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T07:53:56Z","timestamp":1751010836000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-017-1582-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,22]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1007\/s11239-017-1582-1","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,22]]}}}